Abstract

A microfluidic apparatus includes a holder with multiple primary recesses and a plurality of device retaining features and a plurality of microfluidic assay devices configured to be received by the plurality of primary recesses and removably retained by the device retaining features. Each primary recess includes a window opening extending through a lower holder surface. Each microfluidic assay device includes vias extending between opposing upper and lower surfaces, with the lower surface defining a plurality of microfluidic structures, including first scaffold region and a second scaffold region that borders a fluid-permeable boundary portion (optionally comprising microposts) of the first scaffold region. A gas-permeable membrane is affixed to the lower surface of each microfluidic assay device.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
• B01L 9/00 - Supporting devices; Holding devices

Abstract

An electrocorticography array for assessment of electrocorticogram and oxygenation. In some embodiments, electrocorticography array includes a sheet, including a biocompatible polymer, and a siloxane absorbed in the biocompatible polymer, the sheet having a thickness of between 100 microns and 4 mm, and an area of between 3 mm2and 20 cm2.

IPC Classes  ?

• A61B 5/24 - Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof

Abstract

A recycled-aerogel composite includes a multiplicity of swelled crumb rubber particles and a filler. Each swelled crumb rubber particle includes a crumb rubber particle defining pores, and oil distributed throughout the pores. The filler includes a multiplicity of fibers, aerogel material, or both. A modified asphalt binder includes asphalt binder and the recycled-aerogel composite. An asphalt pavement includes the modified asphalt binder and aggregate. Methods of making the modified asphalt binder and a recycled-aerogel composite are described.

IPC Classes  ?

• C08J 11/04 - Recovery or working-up of waste materials of polymers
• E01C 7/26 - Coherent pavings made in situ made of road-metal and binders of road-metal and bituminous binders mixed with other materials, e.g. cement, rubber, leather, fibre

Abstract

Exemplary systems and methods utilize topological smoothing and optimal transportation to estimate a cortical magnification factor. Via these methods, medical practitioners can obtain improved information regarding visual system of a patient

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• G01R 33/48 - NMR imaging systems
• G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
• G06T 7/11 - Region-based segmentation

Abstract

A system receives observation data from structured illumination fluorescence microscopy (SIM) data, and outputs a de-noised image of a fluorescence density. The system employs Bayesian inference to infer various parameters that enable de-noising of observation data. While one embodiment discussed herein is directed at analyzing SIM data, the system can be extended to solve any general tomography problem.

IPC Classes  ?

• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

A system applies Bayesian inference techniques to determine parameters of a camera and an illumination profile for an inhomogeneously-illuminated sample from observation data. The system learns full posterior probability distributions over all parameters involved in the imaging process that works in both high illumination and low illumination regimes.

IPC Classes  ?

• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G02B 21/06 - Means for illuminating specimen

Abstract

Described herein are programmable DNA proteolysis target chimera complexes which can be used to both directly treat a cancer by inhibiting a biochemical pathway overexpressed in a cancer cell and indirectly treat a cancer by recruiting an E3 ligase complex to engage with a protein of interest or mutant thereof and commence proteolysis. Also described herein are methods of using said complexes for treating cancer, and compositions comprising said complexes.

IPC Classes  ?

• A61K 47/66 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
• C07K 14/00 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
• C12N 5/09 - Tumour cells
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 35/00 - Antineoplastic agents

Abstract

A physically inspired model for widefield fluorescence imaging leverages all available spatial and temporal correlations as freely diffusing emitter PSFs overlap to achieve precise tracking in situations where overlap is inevitable. By leveraging all spatiotemporal correlations, the system simultaneously achieves particle localization, links particle localizations across images, and determines the number of particles while self-consistently propagating errors through all steps. This is accomplished within a Bayesian nonparametric paradigm, enabling development of full posteriors over all potential tracks induced by the particles warranted by the data. In contrast, current single particle tracking algorithms treat these steps individually, which results in unreliable tracking when the point spread functions significantly overlap.

IPC Classes  ?

• G01N 21/64 - Fluorescence; Phosphorescence
• G01N 15/14 - Electro-optical investigation
• G02B 21/00 - Microscopes
• G06T 7/246 - Analysis of motion using feature-based methods, e.g. the tracking of corners or segments
• G06T 7/73 - Determining position or orientation of objects or cameras using feature-based methods
• G06T 3/00 - Geometric image transformation in the plane of the image

Abstract

A zwitterionic material includes a substrate including a first polymer, and a second polymer bonded to the first polymer. The second polymer includes a zwitterionic component. Making the zwitterionic material includes coating a polymerizable material on a substrate, and polymerizing the polymerizable material, thereby bonding a second polymer to the substrate, wherein the second polymer comprises the zwitterionic component. The substrate includes the first polymer, and the polymerizable material includes the zwitterionic component.

Abstract

33, where A represents one or more organic cations, one or more inorganic cations, or both, B represents one or more metal cations, and X represents one or more halide anions. A coated substrate includes a substrate and a perovskite precursor composition on the substrate. The perovskite precursor composition comprises a solvent and one or more perovskite precursors, and removing the solvent from the perovskite precursor composition yields a perovskite film on the substrate.

IPC Classes  ?

• H10K 30/50 - Photovoltaic [PV] devices
• H01L 31/00 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof

Abstract

The present invention provides polymers, particles (e.g., microparticles or particles), and compositions thereof for inducing an immune response, preventing or treating a metabolic inhibition in a subject, preventing or treating a disease or disorder, such as cancer, and/or adoptive T cell therapy. The present invention additionally provides kits that find use in the practice of the methods of the invention.

IPC Classes  ?

• A61K 31/70 - Carbohydrates; Sugars; Derivatives thereof
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention provides forskolin, conjugates, prodrugs, nanoparticles, microparticles, or compositions thereof comprising at least one lipid, at least one surfactant, and at least one vitamin E. In some embodiments, the nanoparticles, microparticles, or compositions thereof further comprise at least one targeting agent for an adipose tissue of interest. In some embodiments, forskolin, conjugates, prodrugs, nanoparticles, microparticles, or compositions thereof are delivered to adipose tissue via intrafat injection, hydrogel, or transdermal approaches. In some embodiments, forskolin, conjugates, or prodrugs thereof are incorporated on the surface of nanoparticles or microparticles. In various aspects, the present invention provides methods of increasing the concentration of a cellular cAMP, methods of activating brown adipose tissue or browning white adipose tissue of interest, methods of reducing body fat, inducing weight loss, or improving glucose homeostasis and insulin sensitivity, and/or methods of treating or preventing a metabolic disease or disorder, such as obesity.

IPC Classes  ?

• A61K 35/12 - Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/045 - Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
• A61K 31/423 - Oxazoles condensed with carbocyclic rings
• C12N 5/07 - Animal cells or tissues
• A61K 31/33 - Heterocyclic compounds

Abstract

The present disclosure provides devices, systems, and methods related to electronic biosensors. In particular, the present disclosure provides devices, systems, and methods for fabricating nanometer-scale devices with external circuits using a combination of bottom-up and top-down integration techniques to create self-aligning single-molecule circuits.

IPC Classes  ?

• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Abstract

The present invention relates to particles comprising a metabolite-based polymer (e.g., poly(a-ketoglutarate) (paKG), or a derivative, prodrug, or pharmaceutically acceptable salt thereof), a glycolysis pathway inhibitor (e.g., PFK15, or a derivative, prodmg, or pharmaceutically acceptable salt thereof), and a peptide antigen (e.g., proteolipid protein (PLP) antigen, myelin oligodendrocyte glycoprotein (MOG), myelin-associated glycoprotein (MAG), or fragments or variants thereof) as well as compositions thereof. The present invention also relates to methods of using said particles or compositions thereof for suppressing an immune response and/or preventing or treating a disease or disorder, such as a neurological disease or disorder, trauma, a disease or disorder related to trauma, or any combination thereof.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61L 27/34 - Macromolecular materials
• A61P 37/02 - Immunomodulators
• A61L 31/10 - Macromolecular materials
• A61K 35/12 - Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Abstract

Methods are provided for cleaning a substrate. An exemplary method includes irradiating a pathogenic formation on a surface of the substrate with radiation in a wavelength range of 350 nm to 800 nm, wherein the substrate includes metal particles on the surface of the substrate, and wherein a highest temperature of the metal particles during the irradiation is less than or equal to 45°C; and delaminating the pathogenic formation from the substrate.

IPC Classes  ?

• A61L 2/08 - Radiation
• A01N 25/12 - Powders or granules
• A61K 33/38 - Silver; Compounds thereof
• A01N 55/02 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen and sulfur containing metal atoms
• A01P 1/00 - Disinfectants; Antimicrobial compounds or mixtures thereof
• A61K 6/62 - Photochemical radical initiators
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• B82Y 99/00 - Subject matter not provided for in other groups of this subclass
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

/or/or tissue displacement. Robotic ex-situ actuation may be supplemented with in-situ actuation using a premagnetized element associated with a surgical instrument. A camera and/or optical fiber may be associated with an endoscope to enable visualization of a surgical field and/or provide signals to enable responsive control of a magnetic field source.

IPC Classes  ?

• A61B 34/30 - Surgical robots
• A61B 17/00 - Surgical instruments, devices or methods, e.g. tourniquets

Abstract

A perovskite film includes a host having a perovskite crystal structure and a dopant incorporated into the perovskite crystal structure, wherein the dopant comprises a metal ion, a halogen ion, or both. Light emitting devices and full color displays including the perovskite film provide improved device efficiency and operational lifetime.

IPC Classes  ?

• C01G 21/16 - Halides
• C07F 7/24 - Lead compounds
• H10K 50/80 - Constructional details
• H05B 33/14 - Light sources with substantially two-dimensional radiating surfaces characterised by the chemical or physical composition or the arrangement of the electroluminescent material
• H10K 50/15 - Hole transporting layers
• H10K 50/16 - Electron transporting layers
• H10K 50/17 - Carrier injection layers
• H10K 50/18 - Carrier blocking layers

Abstract

A system and method for determining positional information of a steerable assembly within a body (optionally comprising an animal (e.g., human) body) utilizes a rigid guide tube having a bore through which the steerable assembly and Fiber Bragg Grating (FBG) sensors, the guide tube having a non-linear shape that is conferred to the steerable assembly and is detectable by a FBG detector to define an origin of the steerable assembly. Continued passage of the steerable assembly through the rigid guide tube at a gate position thereof causes the origin to change with time, and the origin is used in conjunction with the FBG sensors to determine a 3D trajectory of the steerable assembly in the body. The 3D trajectory may be further updated responsive to sensing of relative position and relative orientation between the guide tube and the body.

IPC Classes  ?

• A61B 1/005 - Flexible endoscopes
• A61B 5/0285 - Measuring phase velocity of blood waves
• A61B 10/04 - Endoscopic instruments
• G02B 23/24 - Instruments for viewing the inside of hollow bodies, e.g. fibrescopes

Abstract

A multimode free-space coupled filter and a method of forming the filter are disclosed. The filter includes a first layer comprising a dielectric film; a second layer disposed on the first layer, the second layer comprising a dielectric film with a regularly spaced pattern of metal features, wherein the metal features are uniform in size and spacing with a period g and spacing between the features given by 2a, one or more additional first and one or more additional second layers, wherein the one or more additional first layers and the one or more additional second layers are disposed to alternate; and a topmost layer comprising a dielectric film disposed on a top surface of a topmost layer comprising a dielectric film with a regularly spaced pattern of metal features.

IPC Classes  ?

• H01L 23/522 - Arrangements for conducting electric current within the device in operation from one component to another including external interconnections consisting of a multilayer structure of conductive and insulating layers inseparably formed on the semiconductor body
• H01L 21/60 - Attaching leads or other conductive members, to be used for carrying current to or from the device in operation
• H01L 27/04 - Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate including integrated passive circuit elements with at least one potential-jump barrier or surface barrier the substrate being a semiconductor body
• G03F 7/00 - Photomechanical, e.g. photolithographic, production of textured or patterned surfaces, e.g. printed surfaces; Materials therefor, e.g. comprising photoresists; Apparatus specially adapted therefor
• H01G 9/042 - Electrodes characterised by the material

Abstract

A system for brain stimulation and monitoring, the system comprising: an implant comprising: an implant transceiver; a power management and storage unit; one or more electrodes; a recorder unit; and a memory; an external device comprising: a power source; and an external device transceiver configured to send power signals and stimulation signals to the implant transceiver; wherein the external device is configured to wirelessly send power signals and stimulation signals to the implant; wherein the implant is configured to record one or more biosignals from the one or more electrodes and wirelessly communicate the biosignals to the external device.

IPC Classes  ?

• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/375 - Constructional arrangements, e.g. casings

Abstract

This invention is directed to agricultural compositions and methods of using the same. For example, this invention is directed to agricultural compositions comprising a biocrust bacteria inoculum and methods of using the same.

IPC Classes  ?

• A01C 21/00 - Methods of fertilising
• A01N 63/20 - Bacteria; Substances produced thereby or obtained therefrom
• C05F 11/08 - Organic fertilisers containing added bacterial cultures, mycelia or the like
• C05F 17/20 - Preparation of fertilisers characterised by biological or biochemical treatment steps, e.g. composting or fermentation using specific microorganisms or substances, e.g. enzymes, for activating or stimulating the treatment
• C09K 17/00 - Soil-conditioning materials or soil-stabilising materials
• C12N 1/12 - Unicellular algae; Culture media therefor
• C12N 1/20 - Bacteria; Culture media therefor

Abstract

A modified side-emitting optical fiber includes a core comprising an optical fiber and a UV-C transparent polymer coating over the core. An average surface roughness of the UV-C transparent polymer coating is in a range of about 0.3 µm to about 0.7 µm as measured by root mean square of distance difference measurements of the surface of the UV-C transparent polymer coating. Fabricating a modified side-emitting optical fiber includes contacting a coated optical fiber with a solvent, wherein the coated optical fiber comprises a UV-C transparent polymer coating, and dissolving at least a portion of the UV-C transparent polymer coating in the solvent to yield the modified side-emitting optical fiber, wherein an average surface roughness of the UV-C transparent polymer coating is in a range of about 0.3 µm to about 0.7 µm.

IPC Classes  ?

• G02B 6/00 - Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings
• A61L 2/10 - Ultraviolet radiation
• C03C 25/106 - Single coatings

Abstract

An electrospun nanofiber composite includes nanofibers comprising one or more polymers and one or more amino acids incorporated throughout the nanofibers. Forming the electrospun nanofiber composite includes combining one or more amino acids, one or more polymers, and a solvent to yield a mixture; electrospinning the mixture to yield an electrospun nanofiber composite precursor; and heating the electrospun nanofiber composite precursor to form the electrospun nanofiber composite, wherein the one or more amino acids is incorporated throughout the electrospun nanofiber composite.

IPC Classes  ?

• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• B01D 53/62 - Carbon oxides
• D01D 5/00 - Formation of filaments, threads, or the like

Abstract

The present invention provides nucleic acid-loaded virus-like particles (VLPs) that can be produced in plants and are designed to deliver a nucleic acid into plant cells. Also provided are compositions comprising the nucleic acid-loaded VLPs, and methods of making and using the nucleic acid-loaded VLPs.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12N 15/83 - Viral vectors, e.g. cauliflower mosaic virus
• C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
• C12N 15/09 - Recombinant DNA-technology

Abstract

The present disclosure relates to methods of directly measuring absolute length of individual telomeres without any PCR amplification or fluorescent probe hybridization. This method can be performed in a high-throughput 96-well plate format. The disclosure provides a method of processing genomic DNA samples comprising telomeric DNA to release the telomeric DNA from the non-telomeric genomic DNA that has one end tagged with a telomere adapter and the other end ligated with a DNA barcode adapter. The telomeric DNA samples are pooled and purified prior to long-read sequencing in certain embodiments, for example via a nanopore.

IPC Classes  ?

• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• C12Q 1/6825 - Nucleic acid detection involving sensors
• C12Q 1/6855 - Ligating adaptors
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6869 - Methods for sequencing

Abstract

The present disclosure provides compositions and methods related to nucleic acid sensors. In particular, the present disclosure provides nucleic acids molecules that target transcripts of a gene or chromosomal fusion and activate a downstream event, including the production of a detectable signal and/or exert a therapeutic function.

IPC Classes  ?

• C12Q 1/6825 - Nucleic acid detection involving sensors
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/86 - Viral vectors
• C12Q 1/6897 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Abstract

Provided herein is a multivalent recombinant immune complex (RIC) that includes an immunoglobulin heavy chain; at least one epitope tag, wherein the immunoglobulin heavy chain binds the epitope tag; and at least fragments of antigens from at two viral serotypes. In some embodiments, the antigens comprise a dengue virus (DENV) domain III antigen. Related methods and other aspects are also provided.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses
• C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
• A61K 39/295 - Polyvalent viral antigens; Mixtures of viral and bacterial antigens
• C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61P 31/20 - Antivirals for DNA viruses
• A61K 39/29 - Hepatitis virus
• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus

Abstract

Provided herein is a vaccination composition that comprises a recombinant immune complex (RIC) that includes an immunoglobulin heavy chain; an epitope tag, wherein the immunoglobulin heavy chain binds the epitope tag; and at least a fragment of a herpes simplex virus (HSV) type 2 glycoprotein D (HSV2 glycoprotein D). Related methods, recombinant vectors, and other aspects are also provided.

IPC Classes  ?

• A61K 39/245 - Herpetoviridae, e.g. herpes simplex virus
• A61P 31/12 - Antivirals
• A61P 31/20 - Antivirals for DNA viruses
• A61P 31/22 - Antivirals for DNA viruses for herpes viruses
• C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses

Abstract

Provided herein are lipid nanoparticle complex with nanoparticles cloaked in monocyte plasma membrane for effective delivery of drugs. Also provided herein are drug loaded lipid nanoparticle complex for inhibition of YAP/TAZ pathway and methods of using the lipid nanoparticles for treatment of atherosclerosis in a subject in need thereof.

IPC Classes  ?

• A61K 9/127 - Liposomes
• A61K 9/51 - Nanocapsules
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• B82B 3/00 - Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• B82Y 15/00 - Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
• B82Y 40/00 - Manufacture or treatment of nanostructures

Abstract

Described herein are mRNA carrier systems and methods of their use for entering the cytoplasm and expressing carried mRNA, to induce a tumor killing effect. The mRNA carrier systems can comprise DNA or RNA nanostructures. Also described herein are methods of treating cancer using the mRNA carrier systems described herein.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61P 35/00 - Antineoplastic agents
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

A composite material includes an adsorbent support having a carbon block structure defining pores, and titanium (hydr)oxide particles or films bound to the carbon block structure inside the pores. Preparing the composite material includes contacting a porous support having a carbon block structure defining pores with a solution including a solvent and a titanium (hydr)oxide precursor to yield a precursor material, and drying the precursor material to yield a titanium (hydr)oxide-impregnated carbon block. Synthesizing hybrid titanium (hydr)oxides includes combining a solution including a titanium (hydr)oxide precursor and a solvent with one or more metal precursors to yield a precursor solution, and heating the precursor solution to yield the hybrid titanium (hydr)oxides.

IPC Classes  ?

• B01J 21/06 - Silicon, titanium, zirconium or hafnium; Oxides or hydroxides thereof
• B01J 21/18 - Carbon
• B01J 35/00 - Catalysts, in general, characterised by their form or physical properties

Abstract

Provided herein are computer-implemented methods of generating a disease map of a population. In some embodiments, the methods include applying a clustering algorithm to a set of weight and bias values of a trained electronic neural network to generate the disease map of the population. In some embodiments, the electronic neural network has been trained on training data that comprises representations of peptide sequence and binding value pair data sets obtained from reference subjects in the population in which a given peptide sequence and binding value pair data set comprises peptide sequence information and peptide binding values of antibodies to peptides that comprises the peptide sequence information. In some embodiments, the antibodies are from a sample obtained from a given reference subject in the population and are indicative of one or more disease states. Related systems, computer readable media, and additional methods are also provided.

IPC Classes  ?

• G06N 3/02 - Neural networks
• G06N 3/08 - Learning methods
• G06N 20/00 - Machine learning
• G16H 50/80 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G06F 16/29 - Geographical information databases
• G06N 3/04 - Architecture, e.g. interconnection topology
• G06N 7/01 - Probabilistic graphical models, e.g. probabilistic networks
• G16B 40/00 - ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Abstract

Provided herein are nanostructures comprising peptides specific for the extracellular domains of HER1 and/or HER3. Also provided herein are methods for use of the nanostructures to aggregate cells and deliver therapeutic agents to the cells. The nanostructures and methos are useful for treating and/or preventing cancers or other conditions associated with HER1 and/or HER3 overexpression.

IPC Classes  ?

• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 35/00 - Antineoplastic agents
• C07K 14/00 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Abstract

A high efficiency wide-voltage-gain power conversion system and method is disclosed. The system includes a variable-inverter-rectifier-transformer (VIRT) having four pairs of switches forming four half-bridges. Each pair of switches has a top and bottom switch, with the top switch being in one state of "on" and "off" and the bottom switch being in the other state. The states of the four pairs is described by a vector associated with a segment voltage output by the VIRT. The system also includes a converter having a transformer communicatively coupled to the VIRT such that cycling the VIRT through a sequence of vectors generates a waveshape that drives a flux inside a center post of the transformer. The VIRT interfaces with a first voltage, and the converter interfaces with a second. At least one of the input and output voltages varies across a wide voltage range.

IPC Classes  ?

• H01F 17/04 - Fixed inductances of the signal type with magnetic core
• H01F 21/12 - Variable inductances or transformers of the signal type discontinuously variable, e.g. tapped
• H01F 27/24 - Magnetic cores
• H01F 27/34 - Special means for preventing or reducing unwanted electric or magnetic effects, e.g. no-load losses, reactive currents, harmonics, oscillations, leakage fields
• H01F 27/38 - Auxiliary core members; Auxiliary coils or windings
• H01F 27/245 - Magnetic cores made from sheets, e.g. grain-oriented
• H01F 27/28 - Coils; Windings; Conductive connections
• H01F 27/42 - Circuits specially adapted for the purpose of modifying, or compensating for, electric characteristics of transformers, reactors or choke coils
• H02M 3/135 - Conversion of dc power input into dc power output without intermediate conversion into ac by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a thyratron or thyristor type requiring extinguishing means using semiconductor devices only

Abstract

A micro-power generator for portable applications with a micro-scale reformer tube having a diameter of 3mm or less, a plurality of fuel cells within a main reactor chamber, each of the plurality of fuel cells coupled in a cantilevered fashion at a first end to a substrate, the micro-scale reformer configured to receive a fuel/air mixture through an intake. The micro-power generator receives fuel and converts the fuel within the main reactor to a syngas through use of thermal partial oxidation without subsequent formation of soot, and then electrochemically converts the synthesis gas to generate electricity. The reform reaction is made self-sustaining, at least in part, by the heat introduced to the at least one reformer tube by waste gas expelled into the main reactor chamber when an equivalence ratio is maintained above a threshold ratio.

IPC Classes  ?

• H01M 8/0612 - Combination of fuel cells with means for production of reactants or for treatment of residues with means for production of gaseous reactants from carbon-containing material
• H01M 8/1246 - Fuel cells with solid electrolytes operating at high temperature, e.g. with stabilised ZrO2 electrolyte characterised by the process of manufacturing or by the material of the electrolyte the electrolyte consisting of oxides

Abstract

The present invention relates anti-microbial antibody signatures related to lung tumors, including benign tumors and adenocarcinomas. Disclosed herein are antibody panels comprising antigens from bacteria and/or viruses for use in early and accurate diagnosis of lung cancer and for reducing false positive lung carcinoma diagnoses from CT screening.

IPC Classes  ?

• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
• C07K 14/05 - Epstein-Barr virus
• C07K 14/205 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)

Abstract

The invention encompasses polysalt compositions, methods of use, and materials thereof.

IPC Classes  ?

• C08G 69/26 - Polyamides derived from amino carboxylic acids or from polyamines and polycarboxylic acids derived from polyamines and polycarboxylic acids
• C08G 73/10 - Polyimides; Polyester-imides; Polyamide-imides; Polyamide acids or similar polyimide precursors
• C08F 120/06 - Acrylic acid; Methacrylic acid; Metal salts or ammonium salts thereof

Abstract

The present disclosure provides compositions and methods related to antiviral therapeutics. In particular, the present disclosure provides a highly modular platform useful for the development and production of multivalent biomolecules capable targeting and neutralizing a virus.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
• A61P 31/12 - Antivirals

Abstract

An indicator system comprising permanganate, an organic reducing agent, an acid, and an inorganic perchlorate salt is provided herein. Methods for using the indicator system to monitor the integrity of a biospecimen are also provided. The systems and methods herein may provide easy-to-use, individual aliquot-level thawed-state indicators for indicating biospecimen time-temperature exposure.

IPC Classes  ?

• A01N 1/02 - Preservation of living parts
• G01K 3/02 - Thermometers giving results other than momentary value of temperature giving integrated values
• G01K 3/04 - Thermometers giving results other than momentary value of temperature giving integrated values in respect of time

Abstract

burgdorferiburgdorferi proteome that can be used for detection of Lyme disease in patient samples.

IPC Classes  ?

• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
• G01N 33/577 - Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
• A61K 31/545 - Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine
• A61K 31/65 - Tetracyclines
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• C12N 15/65 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers

Abstract

Diagnostic metabolites and methods of using the metabolites for the diagnosis of autism spectrum disorder (ASD) are provided. The metabolites comprise a collection of 47 metabolites that were significantly different between the autistic and typically developing groups, and combinations of two or more of the metabolites are used to accurately diagnose ASD.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

Methods of analyzing antibodies in samples are provided. In some embodiments, the methods include contacting a sample with a plurality of plasmonic metal nanoparticles (MNPs) having a viral antigen binding moiety bound to its surface and a viral antigen that comprises two or more epitopes that bind to the viral antigen binding moiety to form a binding composition. In these embodiments, the methods include detecting an extinction signal intensity to identify antibody capabilities in the sample, including the quantity and quality of the antibody. Related systems and other methods are also provided.

IPC Classes  ?

• G01N 33/553 - Metal or metal coated
• G01N 21/25 - Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
• G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
• G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

A system and method for non-contact heart rate estimation. In some embodiments, the method includes filtering a radar range history with a first filter, to form a first filtered radar range history; and forming a first estimate of the heart rate of a subject based on the first filtered radar range history, the first filter having a passband including a frequency greater than 20 Hs.

IPC Classes  ?

• A61B 5/0245 - Measuring pulse rate or heart rate using sensing means generating electric signals
• A61B 5/024 - Measuring pulse rate or heart rate
• G01S 13/88 - Radar or analogous systems, specially adapted for specific applications

Abstract

Making a dendritic identifier includes compressing a drop of liquid between a surface of a stamp and a surface of a substrate, and separating the stamp and the substrate to yield a dendritic identifier on the surface of the substrate.

IPC Classes  ?

• B29C 59/02 - Surface shaping, e.g. embossing; Apparatus therefor by mechanical means, e.g. pressing
• G06K 19/06 - Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the kind of the digital marking, e.g. shape, nature, code
• B32B 37/02 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by a sequence of laminating steps, e.g. by adding new layers at consecutive laminating stations
• G06V 20/80 - Recognising image objects characterised by unique random patterns
• B05B 1/02 - Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to produce a jet, spray, or other discharge of particular shape or nature, e.g. in single drops
• B23K 26/352 - Working by laser beam, e.g. welding, cutting or boring for surface treatment
• B42D 25/30 - Identification or security features, e.g. for preventing forgery

Abstract

This invention is directed to crystalline forms of cannabinoid acids, producing crystalline forms, and methods of use thereof.

IPC Classes  ?

• C07C 51/00 - Preparation of carboxylic acids or their salts, halides, or anhydrides
• C12P 7/42 - Hydroxy carboxylic acids
• C07C 51/42 - Separation; Purification; Stabilisation; Use of additives
• C07C 69/94 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings

Abstract

Reinforcement learning of interference-aware beam pattern design is provided. Employing large antenna arrays is a characteristic of millimeter wave (mmWave) and terahertz (THz) communication systems. Embodiments described herein provide an efficient deep reinforcement learning based beam pattern design algorithm that achieves interference awareness. This is done by not requiring the channel knowledge of both desired user and the interference users. Simulation results show that the developed solution is capable of finding a well-shaped beam pattern that significantly suppresses the interference while sacrificing only negligible beamforming/combining gain from the desired user, based only on power measurements. Furthermore, a platform and results based on real measurements are also presented, which indicates the effectiveness and robustness of the disclosed interference-aware beam pattern design approach in a practical system.

IPC Classes  ?

• H01Q 21/00 - Antenna arrays or systems
• G06N 3/092 - Reinforcement learning
• H04B 17/10 - Monitoring; Testing of transmitters
• H04B 17/20 - Monitoring; Testing of receivers

Abstract

A corner flow accelerometer device for reduced gravity applications comprises a capillary tube, wherein the capillary tube is partially filled with a capillary fluid, and wherein the capillary tube includes at least one corner configured to enhance capillary flow. A corner flow accelerometer device for reduced gravity applications comprises a hollow square prism comprising a capillary tube, wherein the square prism is partially filled with a capillary fluid comprising silicone oil, and wherein the square prism is anchored to a weight inside a gyroscope body. A gravity monitoring method comprises providing the corner flow accelerometer device as describe above, measuring a fluid height or meniscus curvature due to capillary flow, calculating a dimensionless Bond number based on the measured fluid height or meniscus curvature, wherein the dimensionless Bond number comprises a ratio between gravitational and surface forces, and calculating a gravitational force based the Bond number.

IPC Classes  ?

• G01P 15/02 - Measuring acceleration; Measuring deceleration; Measuring shock, i.e. sudden change of acceleration by making use of inertia forces
• G01P 15/03 - Measuring acceleration; Measuring deceleration; Measuring shock, i.e. sudden change of acceleration by making use of inertia forces by using non-electrical means
• A61F 2/82 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents

Abstract

Disclosed herein are compositions and methods for treating cancer. The methods can comprise administrating to a subject with cancer a therapeutically effective amount of an oncolytic virus and a therapeutically-effective amount of a nuclear export inhibitor. Methods disclosed herein can convert nonpermissive or semi-permissive cancers to permissive cancers that are susceptible to infection and killing by oncolytic viruses.

IPC Classes  ?

• A61K 35/768 - Oncolytic viruses not provided for in groups
• A61K 39/275 - Poxviridae, e.g. avipoxvirus

Abstract

The present disclosure provides compositions and methods related to nucleic acid sensors. In particular, the present disclosure provides membrane-spanning nucleic acid sensors, signal transducers, and molecular amplifiers for lysis-free detection of internal nucleic acids.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding

Abstract

Disclosed herein are methods of treating a lung disorder. In some embodiments, the lung disorder includes an acute respiratory syndrome. In some embodiments, the treatment includes administering to a subject in need thereof, a modified Serp-1 protein. The modified Serp-1 protein may include a therapeutic enhancing moiety. In some embodiments, the therapeutic enhancing moiety is a water soluble polymer such as polyethylene glycol.

IPC Classes  ?

• C07K 14/81 - Protease inhibitors
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

Wound healing is a process by which these wounds on the skin of a subject heal and eventually close. When the injured surface is large, becomes infected, or in patients with poor healing capacity such as diabetics or the elderly or bedridden patients, then wound healing can be prolonged and lead to chronic ulceration and further complications with even limb loss or increased morbidity and mortality. This invention is directed to a topical formulation for promoting wound healing, and wound dressings and bandages comprising the same.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
• A61K 38/16 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Abstract

Described herein is a process in which filamentous fungi can be used to create textile or paper materials with tunable properties. The textiles can range from leather-like to paper-like depending on the species of fungi used and the growth conditions. The method of production utilizes the tendency of filamentous fungi to form films on still liquids, in order to generate many mycelial mats concurrently. These mats can then be layered to create textile materials, paper materials, and other material types having varying thickness, composition, and mechanical properties.

IPC Classes  ?

• C12N 1/14 - Fungi ; Culture media therefor
• D06M 15/03 - Polysaccharides or derivatives thereof
• D06M 15/05 - Cellulose or derivatives thereof
• B29C 70/06 - Fibrous reinforcements only
• B29C 70/42 - Shaping or impregnating by compression for producing articles of definite length, i.e. discrete articles
• C08J 5/24 - Impregnating materials with prepolymers which can be polymerised in situ, e.g. manufacture of prepregs

Abstract

Described are platforms, systems, media, and methods for evaluating, monitoring, and/or treating a subject for brain injury based on machine learning analysis of one or more of brain imaging features, clinical features, demographic features, or speech features.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G10L 25/66 - Speech or voice analysis techniques not restricted to a single one of groups specially adapted for particular use for comparison or discrimination for extracting parameters related to health condition
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• G06N 20/00 - Machine learning

Abstract

An active shoulder rest, comprising: at least one sound diffusion speaker; at least one actuator; and at least one amplifier, wherein the at least one sound diffusion speaker and the at least one actuator are connected to the at least one amplifier. The active shoulder rest may further comprise a body, and a damping material within the body. The active shoulder rest may further comprise at least one port configured for a microphone pickup.

IPC Classes  ?

• G10D 3/18 - Chin-rests, hand-rests, shoulder rests or guards being removable from, or integral with the instrument
• G10G 5/00 - Supports for musical instruments
• G10H 3/18 - Instruments in which the tones are generated by electromechanical means using mechanical resonant generators, e.g. strings or percussion instruments, the tones of which are picked up by electromechanical transducers, the electrical signals being further manipulated or amplified and subsequently converted to sound by a lo using mechanically actuated vibrators with pick-up means using strings, e.g. electric guitars

Abstract

A device and method for measuring excreted ketones in a body fluid. The device includes a housing and a sensor positioned within the housing. The sensor includes a body, and a cavity formed in the body, the cavity configured to hold a colorimetric sensing liquid, the body including a ketone permeable medium and a hydrophobic membrane with or without an alkaline material to prevent acidic gases or volatile compound interferents. The sensor is configured to detect presence of ketone in the body fluid in contact with the housing.

IPC Classes  ?

• G01N 33/64 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving ketones
• G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour

Abstract

A radar stethoscope system (12) and method for respiration and heart sound assessment is provided. Embodiments present a method to measure acoustics related to breathing and heartbeat sounds using small-scale radars. Acoustic data derived from the radar return measurements can be based on phase changes of the radar return measurements over a period of time. The radar stethoscope (12) can capture and identify respiratory and heart acoustics as traditionally captured by a clinical stethoscope. Using advanced radar processing algorithms, these acoustic signals can be recovered from a distance and without making contact with the patient (14).

IPC Classes  ?

• A61B 7/04 - Electric stethoscopes
• A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
• A61B 5/0507 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves using microwaves or terahertz waves
• A61B 5/08 - Measuring devices for evaluating the respiratory organs
• A61B 5/113 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb occurring during breathing
• G01S 13/02 - Systems using reflection of radio waves, e.g. primary radar systems; Analogous systems

Abstract

The present invention provides antimicrobial nanoparticles or compositions thereof comprising at least one phytochemical or bioactive compound, at least one lipid, at least one surfactant, and at least one vitamin E. In some embodiments, the antimicrobial nanoparticles or compositions thereof further comprise at least one coating agent. In some embodiments, the antimicrobial nanoparticles or compositions thereof are an edible coating. In various aspects, the present invention relates to methods of reducing or inhibiting the activity or level of or preventing the growth of at least one microorganism on a surface of an element. In some aspects, the present invention relates to methods of increasing a shelf-life of food and/or maintaining and improving food nutrients and/or nutrition values. In other aspects, the present invention relates to methods of delivering at least one nutritional or bioactive agent for preventing and treating various disorders and diseases.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A23L 29/00 - Foods or foodstuffs containing additives; Preparation or treatment thereof
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23L 33/15 - Vitamins
• A61K 9/127 - Liposomes
• A61K 31/05 - Phenols
• A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• A61P 31/04 - Antibacterial agents

Abstract

The present invention relates to a method for decreasing microbial biomass and biodegradation rates of in situ bioremediation system using acetylene as the inhibitor.

IPC Classes  ?

• F17C 11/00 - Use of gas-solvents or gas-sorbents in vessels
• C07C 11/24 - Acetylene
• F02B 43/12 - Methods of operating

Abstract

Provided herein are methods of quantifying protein folding and stability. Some embodiments provide methods of detecting a misfolded target protein that include determining a growth rate or relative fitness of a first cell population that comprises a first fusion polypeptide comprising a first variant of a target protein disposed between segments of a toxic indicator protein, which segments together induce the first cell population to grow at a lower rate when the target protein is relatively less misfolded than when the target protein is relatively more misfolded, and determining that the growth rate or fitness of the first cell population varies from a growth rate or fitness of a second cell population that comprises a second fusion polypeptide comprising a second variant of the target protein disposed between the segments of the toxic Indicator protein. Related nucleic acids, kits, and systems are also provided.

IPC Classes  ?

• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
• G01N 33/573 - Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

Described herein is a DNA nanotechnology-based platform for the delivery of nucleic acids into cells. The delivery platform relies on compacting cargo mRNA and/or ssDNA into single folded nanostructures that act as the primary structural vehicle material for nanoparticle delivery to cells. The described compositions and methods provide an alternative to packaging mRNA or ssDNA into lipid nanoparticle vehicles, which have complex formulation properties. Also described herein are strategies for protecting mRNA and/or ssDNA cargo and helping these nucleic acid molecules escape the endosome into the cytoplasm using a cationic peptide-PEG coating.

IPC Classes  ?

• A61K 9/16 - Agglomerates; Granulates; Microbeadlets
• A61K 9/50 - Microcapsules
• A61K 9/14 - Particulate form, e.g. powders
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61K 9/127 - Liposomes

Abstract

Described herein are compositions comprising RNA origami (RNAOG) which include 5-fluorouracil (5FU) or analogues thereof are described which can be used to both directly treat a cancer by inhibiting a biochemical pathway overexpressed in a cancer cell and indirectly treat a cancer by inducing an anti-cancer immune response. Also described herein are methods of using said compositions for treating cancer, inducing an anti-cancer immune response, and/or killing a cancer cell.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/117 - Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention provides nanoparticles or conjugates comprising at least one ligand that selectively targets major facilitator superfamily domain-containing protein-2a (MFSD2A). In various embodiments, the nanoparticles or conjugates of the invention target at least one cell comprising MFSD2A (e.g., endothelial cells of blood brain barrier). In some embodiments, the nanoparticles or conjugates of the invention cross the blood brain barrier and/or blood retinal barrier. In other aspects, the present invention relates to methods for in vivo delivery of diagnostic and/or therapeutic agents to a brain. In other aspects, the present invention relates to methods of preventing or treating a neurological or cognitive disease or disorder using the nanoparticles or conjugates of the invention.

IPC Classes  ?

• A61K 9/14 - Particulate form, e.g. powders
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 9/127 - Liposomes
• A61P 25/00 - Drugs for disorders of the nervous system
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention provides a sustained drug release system comprising IL-2 and anti-IL-2 incorporated into a thermosensitive hydrogel that is engineered to be in liquid form at low temperatures for delivery, but form a hydrogel at physiological body temperatures to act as a sustained release platform. The thermostable hydrogel solution slowly releases IL-2 and anti-IL-2 to provide optimal concentrations for effective treatment of autoimmune diseases.

IPC Classes  ?

• A61L 31/14 - Materials characterised by their function or physical properties
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/20 - Interleukins
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 9/06 - Ointments; Bases therefor

Abstract

in situin situ in situ single-cell sequencing technologies are only able to work with RNA, and must first convert DNA to RNA, the method of this disclosure operates directly on DNA as well as on RNA. Thus, it simultaneously sequences each single cell's genome and transcriptome.

IPC Classes  ?

• C12Q 1/6844 - Nucleic acid amplification reactions
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6851 - Quantitative amplification

Abstract

Disclosed herein are systems and methods for Magnetic Resonance Electrical Impedance Tomography (MREIT). A system for imaging biological tissue comprises a controller, a multifrequency arbitrary-waveform constant-current source, a Howland constant-current source, and a digital-to-analog converter. The controller is configured to generate a multifrequency magnetic resonance electrical impedance tomography sequence. The generation comprises producing, by the controller, a digital sequence, and converting, by the digital-to-analog converter, the digital sequence to an analog sequence. The generation may further comprise: producing, by the Howland constant-current source, a standard magnetic resonance electrical impedance tomography sequence based on the analog sequence; producing, by the multifrequency arbitrary-waveform constant-current source, a sine wave at one or more predetermined frequencies; and modulating the standard magnetic resonance electrical impedance tomography sequence with the sine wave. A method of measuring an electrical property of a biological tissue comprises imaging the biological tissue using this system.

IPC Classes  ?

• A61B 5/0536 - Impedance imaging, e.g. by tomography
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• G01R 33/54 - Signal processing systems, e.g. using pulse sequences

Abstract

Provided herein are methods of identifying neoantigens for diagnosing, treating, and preventing cancer. Also provided herein are methods of measuring antibody response to one or more frameshift peptides caused by exon 1 mis-initiation. Also disclosed are methods and compositions for administering identified neoantigens for the treatment and prevention of cancer.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
• G01N 33/533 - Production of labelled immunochemicals with fluorescent label
• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer

Abstract

The present disclosure relates to methods for monitoring effectiveness of a treatment of an autism spectrum disorder (ASD) by analyzing an ASD patient's gut microbiota based on stool samples. Also provided are software for implementing the methods, and kits for performing the methods.

IPC Classes  ?

• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• A61K 35/74 - Bacteria
• A61K 35/741 - Probiotics
• A61K 35/745 - Bifidobacteria

Abstract

Using deep learning, imaging harmonization among images produced with differing PET tracers is achieved. A method may include providing an original PET image of the brain using an original PET tracer, providing a target PET tracer, and converting, using a deep learning neural network, the original PET image into a target PET image simulating the image that would be obtained had the target PET tracer been used.

IPC Classes  ?

• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• A61B 6/00 - Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
• G01R 33/48 - NMR imaging systems

Abstract

A fast-tracking phase-locked-loop (PLL) with an analog mixer for phase detection and correction is provided. A frequency lock loop architecture as described herein is used for a PLL that can lock the phase of a local oscillator to an input reference signal of arbitrarily high frequency, even if the local oscillator and the input reference signal frequencies are originally very far apart. To accommodate arbitrarily high frequency input reference signals, embodiments use an analog mixer for the phase detector, rather than a phase-frequency detector (PFD). The analog mixer can be designed to operate on input signals with frequencies of 10's of GHz, whereas the PFD is limited to input frequencies of less than 1 GHz. Embodiments use a new architecture utilizing the concept of Hartley Image Rejection receiver architecture in a frequency lock loop, which enables the PLL to adjust the local oscillator frequency to be brought within the frequency locking range of the analog mixer.

IPC Classes  ?

• H03L 7/07 - Automatic control of frequency or phase; Synchronisation using a reference signal applied to a frequency- or phase-locked loop using several loops, e.g. for redundant clock signal generation
• H03L 7/085 - Automatic control of frequency or phase; Synchronisation using a reference signal applied to a frequency- or phase-locked loop - Details of the phase-locked loop concerning mainly the frequency- or phase-detection arrangement including the filtering or amplification of its output signal
• H03L 7/095 - Automatic control of frequency or phase; Synchronisation using a reference signal applied to a frequency- or phase-locked loop - Details of the phase-locked loop concerning mainly the frequency- or phase-detection arrangement including the filtering or amplification of its output signal using a lock detector
• H03L 7/20 - Indirect frequency synthesis, i.e. generating a desired one of a number of predetermined frequencies using a frequency- or phase-locked loop using a harmonic phase-locked loop, i.e. a loop which can be locked to one of a number of harmonically related frequencies applied to it
• H03L 7/22 - Indirect frequency synthesis, i.e. generating a desired one of a number of predetermined frequencies using a frequency- or phase-locked loop using more than one loop
• H03L 7/06 - Automatic control of frequency or phase; Synchronisation using a reference signal applied to a frequency- or phase-locked loop
• H03L 7/08 - Automatic control of frequency or phase; Synchronisation using a reference signal applied to a frequency- or phase-locked loop - Details of the phase-locked loop
• H03L 7/081 - Automatic control of frequency or phase; Synchronisation using a reference signal applied to a frequency- or phase-locked loop - Details of the phase-locked loop provided with an additional controlled phase shifter
• H03L 7/083 - Automatic control of frequency or phase; Synchronisation using a reference signal applied to a frequency- or phase-locked loop - Details of the phase-locked loop the reference signal being additionally directly applied to the generator
• H03L 7/087 - Automatic control of frequency or phase; Synchronisation using a reference signal applied to a frequency- or phase-locked loop - Details of the phase-locked loop concerning mainly the frequency- or phase-detection arrangement including the filtering or amplification of its output signal using at least two phase detectors or a frequency and phase detector in the loop
• H03L 7/091 - Automatic control of frequency or phase; Synchronisation using a reference signal applied to a frequency- or phase-locked loop - Details of the phase-locked loop concerning mainly the frequency- or phase-detection arrangement including the filtering or amplification of its output signal the phase or frequency detector using a sampling device

Abstract

Preparing a metal-containing solution or gel includes combining a metal oxide and a liquid comprising a polar organic solvent to yield a mixture, wherein the metal oxide comprises hydrogen-bonded molecular chains, and each molecular chain comprises: a metal from Groups 4 – 6; at least one oxyanion of a main group element from Groups 15 and 16 bound to the metal through a polar covalent bond, wherein the at least one oxyanion is optionally protonated; and at least one water molecule bound to the metal through a polar covalent bond; and heating the mixture to yield a solution or gel comprising the polar organic solvent and the metal. The solution or gel can be acidic.

IPC Classes  ?

• C04B 38/00 - Porous mortars, concrete, artificial stone or ceramic ware; Preparation thereof
• C04B 35/515 - Shaped ceramic products characterised by their composition; Ceramic compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxides
• B01J 13/00 - Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons

Abstract

Disclosed are a nanopore-optical electronic device and a method for sequencing a biomolecule and modifications thereof. The nanopore-optical electronic device includes: a cis-fluidic chamber and a trans-fluidic chamber fabricated in a planar substrate; a nano-fluidic channel in between and connecting the cis-fluidic chamber and the trans-fluidic chamber; a first electrode and a second electrode sealed in the nano-fluidic channel and forming a nanogap/nanopore therebetween; a third electrode and fourth electrode disposed in the cis-fluidic chamber and the trans-fluidic chamber, respectively; an optical coupling element coupling an electromagnetic beam with the nanogap; an optical detector detecting an optical signal from the nanogap when a biomolecule translocates through the nanopore; and a current-measuring circuit concurrently measuring a tunneling current and ionic current when the biomolecule translocates through the nanopore. The recorded optical signal and tunneling current and ionic current signals are coincidental in time and colocalized in space.

IPC Classes  ?

• G01N 33/487 - Physical analysis of biological material of liquid biological material
• G01N 27/327 - Biochemical electrodes
• G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated
• G01N 21/64 - Fluorescence; Phosphorescence
• C12Q 1/6869 - Methods for sequencing

Abstract

The present invention provides nucleic acid-loaded virus-like particles (VLPs) that can be produced in plants and are designed to deliver a nucleic acid into mammalian cells. Also provided are pharmaceutical compositions comprising the nucleic acid-loaded VLPs, and methods of making and using the nucleic acid-loaded VLPs.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Described herein are means for implementing a cloud-based health, nutritional, and body composition analysis platform, in which models are utilized to provide personalized data for health and nutritional counseling. For example, there is a there is a specially configured system (e.g., a "MORPHOGRAM" cloud-based platform) having means for prompting transmitting a GUI for display via a user device specifying instructions to manually determine and enter body metric measurements for a patient; means for receiving inputs providing one or more of (i) the body metric for the patient, (ii) pedometer data for the patient, and (iii) fitness data for the patient; means for populating a personalized risk monitoring profile for the patient by calculating anthropometric indicators; determining a physical activity level for the patient; determining a body type; calculating a physiological lean body mass and percentage of body fat; calculating a target physiological; and retransmitting the GUI to display the personalized risk monitoring profile for the patient based on the inputs received, determined. Other related embodiments are disclosed.

IPC Classes  ?

• G16H 20/60 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
• G09B 5/02 - Electrically-operated educational appliances with visual presentation of the material to be studied, e.g. using film strip
• G09B 19/00 - Teaching not covered by other main groups of this subclass
• G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation

Abstract

The present disclosure relates to DNA-peptide hybrid molecules. In some embodiments, the DNA-peptide hybrid molecules comprise target-specific binding peptides which selectively bind to a target molecule. Methods of using DNA-peptide hybrid molecules in the treatment of diseases or disorders are also provided.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 39/385 - Haptens or antigens, bound to carriers
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith

Abstract

The present disclosure relates to the use of DNA-peptide hybrid molecules to detect target molecules in a sample. In some embodiments, the DNA-peptide hybrid molecules comprise target-specific binding peptides which selectively bind to a target molecule. Kits comprising DNA-peptide hybrid molecules are also provided.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• G01N 33/537 - Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
• C12Q 1/6834 - Enzymatic or biochemical coupling of nucleic acids to a solid phase
• C12Q 1/6825 - Nucleic acid detection involving sensors

Abstract

The present disclosure relates to DNA-peptide hybrid molecules. In some embodiments, the DNA-peptide hybrid molecules comprise target-specific binding peptides which selectively bind to SARS-CoV-2 surface glycoprotein. Methods of using DNA-peptide hybrid molecules in the treatment of SARS-CoV-2 infection are also provided. Where the DNA nanostrucure is a three-helix bundle or a four-helix bundle.

IPC Classes  ?

• A61P 31/14 - Antivirals for RNA viruses
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

Identifying a test pattern includes positioning a test pattern that includes a first multiplicity of particles that reflect or emit light in the field of view of a first imaging device; illuminating the test pattern with light from a first light source; obtaining, with the first imaging device, a first test image of light reflected by the first multiplicity of particles; and comparing the first test image with a first reference image of a reference pattern obtained by a second imaging device.

IPC Classes  ?

• G06F 17/00 - Digital computing or data processing equipment or methods, specially adapted for specific functions
• G02F 1/1335 - Structural association of cells with optical devices, e.g. polarisers or reflectors
• G06K 19/08 - Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the kind of the digital marking, e.g. shape, nature, code using markings of different kinds in the same record carrier, e.g. one marking being sensed by optical and the other by magnetic means
• G07D 7/005 - Testing security markings invisible to the naked eye, e.g. verifying thickened lines or unobtrusive markings or alterations
• G07D 7/12 - Visible light, infrared or ultraviolet radiation

Abstract

The present disclosure relates to DNA nanocarriers and methods of use for stimulating an immune response in a host. In some embodiments, the DNA nanocarriers comprise SARS-CoV-2 surface glycoprotein.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 31/14 - Antivirals for RNA viruses
• A61P 37/04 - Immunostimulants
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• A61K 38/16 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

The present invention biomaterial-based composite ink formulations for use in endoscopic imaging (including in colon tattooing) procedures and their methods of production. The biomaterial-based composite ink formulations comprise at least one contrast agent selected from the group consisting of: iron oxide, copper oxide, carbon nanotube, and graphene oxide; and at least one polysaccharide-based biomaterial selected from chitosan or its derivative. The contrast agents are preferably nanoparticles.

IPC Classes  ?

• C09D 11/324 - Pigment inks containing carbon black
• C09D 11/322 - Pigment inks
• C09D 11/30 - Inkjet printing inks
• C09D 11/38 - Inkjet printing inks characterised by non-macromolecular additives other than solvents, pigments or dyes

Abstract

Dietary supplement compositions and methods of use thereof in subjects who are pregnant, trying to become pregnant, nursing and/or lactating are provided.

IPC Classes  ?

• A23L 33/155 - Vitamins A or D
• A23L 33/16 - Inorganic salts, minerals or trace elements

Abstract

Provided herein are methods of detecting a neurological and/or physical condition in a subject. The methods include receiving physical intensity measures and/or stability measures from the subject to produce a subject data set. The methods also include applying a computational model of temporal and spatial data indicative of the neurological and/or physical condition to the subject data set to identify a substantial match between at least a subset of the subject data set and the computational model of temporal and spatial data. Additional methods as well as related systems and computer readable media are also provided.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• G06F 17/16 - Matrix or vector computation

Abstract

A nanostructure comprising: a) a base plate sheet comprising a single-duplex layer comprised of DNA origami configured in a planar arrangement, b) a pore configured within the center of the base plate sheet, and c) a multi-duplex layer-thick wall comprising a single-duplex layer comprised of DNA origami that extends downward from the base plate sheet on the periphery of the pore, wherein the base plate sheet comprises a single-stranded DNA region on the bottom surface for lipid membrane anchor modification.

IPC Classes  ?

• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• B82Y 40/00 - Manufacture or treatment of nanostructures
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites

Abstract

Described herein are RNA sequence (including siRNA, shRNA, and/or mRNA) carrier platforms for rapid and targeted delivery of siRNAs, shRNAs, and/or mRNAs into cytoplasm of tumor cells, to induce a tumor killing effect. Also described herein is are methods of treating cancer using the RNA sequence carrier platforms described herein.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• C07K 14/00 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• C07K 19/00 - Hybrid peptides

Abstract

A device and method for passive collection of atmospheric CO2 is disclosed. The device includes a chamber having an inner wall, an outer wall, an annular void between the inner and outer walls, and a sump connecting the annular void and an inner cylinder. The device also includes a capture structure having a sorbent material and movable between open and closed configurations. The device includes a water delivery device with a pump and a water applicator positioned within the annular void to dispense water onto the outer wall. The pump transfers water from the sump to the applicator. The open configuration includes the sorbent exposed and allowed to capture CO2. The closed configuration includes the capture structure being enclosed inside the chamber such that a heated water vapor releases captured CO2. The vapor is created by the solar heating of the outer wall and the water dispensed within.

IPC Classes  ?

• B01D 53/04 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography with stationary adsorbents
• B01D 46/00 - Filters or filtering processes specially modified for separating dispersed particles from gases or vapours
• B01D 53/14 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption

Abstract

Provided herein are methods of generating a trained classifier at least partially using a computer. The methods include training a Restricted Boltzmann Machine (RBM) using at least a first training dataset that comprises sequence information corresponding to a population of aptamers, and/or one or more descriptors thereof, which aptamers comprise a minimum threshold binding affinity to a target biomolecule to produce a trained RBM model. Additional methods as well as related systems and computer readable media are also provided.

IPC Classes  ?

• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
• G06K 9/00 - Methods or arrangements for reading or recognising printed or written characters or for recognising patterns, e.g. fingerprints
• G08F 9/50 -

Abstract

A system for detecting one or more inhomogeneities in a sample (e.g., biological tissue) is disclosed. The system comprises a pulser-receiver, first and second ultrasound transducers, and a processor. The first ultrasound transducer may generate a high frequency ultrasound (HFU) signal in response to electrical pulses from the pulser-receiver, whereby the HFU signal is scattered through the sample and received by the second ultrasound transducer. An electronic signal indicative of the scattered HFU signal is received by the processor via the pulser-receiver. The signal is windowed, converted to frequency domain via fast Fourier transform, and assessed for peak quantity and peak frequencies within resonant frequency bands associated with the inhomogeneities. Inhomogeneities in the sample may be indicated by a peak quantity greater than a baseline value associated with homogenous samples and/or peaks at new frequencies with respect to a baseline spectrum associated with homogenous samples.

IPC Classes  ?

• G01S 15/89 - Sonar systems specially adapted for specific applications for mapping or imaging
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves

Abstract

The disclosure relates to a method of producing a multi-metal catalyst film and of producing a reactor system for catalytic removal of a wide variety of contaminants (for example, nitrate, nitrite, perchlorate, chlorate, chromate, selenate, chlorophenols, 2,4-D, dicamba, atrazine, trichloroacetic acid, bromochloroiodomethane, NDMA, TCE, TCA, chloroform, freons, RDX, HMX, TNT, PFOA, and PFOS) from water and wastewater. The disclosure also relates to a method of using the multi-metal catalyst for the removal of such contaminants and a system comprising the multi-metal catalyst film for removing such contaminants.

IPC Classes  ?

• B01D 15/26 - Selective adsorption, e.g. chromatography characterised by the separation mechanism
• B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
• B01D 69/14 - Dynamic membranes
• C02F 1/72 - Treatment of water, waste water, or sewage by oxidation
• B01D 15/10 - Selective adsorption, e.g. chromatography characterised by constructional or operational features
• B01D 53/94 - Chemical or biological purification of waste gases of engine exhaust gases by catalytic processes
• B01D 69/08 - Hollow fibre membranes
• B01D 3/34 - Distillation or related exchange processes in which liquids are contacted with gaseous media, e.g. stripping with one or more auxiliary substances

Abstract

The present disclosure provides compositions and methods related to the detection of coccidioidomycosis (Valley fever). In particular, the present disclosure provides novel compositions and methods related to the detection and/or quantification of coccidioidomycosis in a subject using an enzyme-linked immunoassay (ELISA) that measures coccidioidal CTS1 antigen and/or anti-CTS1 antibodies in human serum.

IPC Classes  ?

• G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor
• G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• G01N 33/573 - Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes

Abstract

Systems and methods for using machine learning to improve disease diagnostics are provided. A method can include obtaining, using a peptide array, peptide sequence data and peptide binding values from one or more samples, wherein the peptide sequence data and the peptide binding values correspond to a plurality of conditions; for each of the one or more samples, normalizing the peptide binding values according to a median binding value of peptides associated with the peptide array; and training a regressor using dense compact representations of the peptide sequence data and peptide binding values. The method can further include providing an output of the regressor to a classifier, wherein the classifier is configured to determine whether the patient has one of the plurality of conditions based on the output of the regressor.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor

Abstract

Provided herein are methods of detecting severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in a sample. The methods include contacting the sample with a plurality of gold nanoparticles (AuNPs) and/or other plasmonic metal nanoparticles (MNPs) that are conjugated with at least two sets of antibodies, or antigen binding portions thereof, that binds to at least first and second epitopes of SARS-CoV-2 proteins, such as receptor-binding domain (RBDs) under conditions sufficient for the antibodies, or the antigen binding portions thereof, to bind to the first and second epitopes of the SARS-CoV-2 proteins in the sample to produce bound SARS-CoV-2 proteins. The methods also include detecting the SARS-CoV-2 proteins when aggregations of the bound SARS-CoV-2 proteins form with one another. Related compositions, reaction mixtures, devices, kits, and systems are also provided.

IPC Classes  ?

• A61K 33/242 - Gold; Compounds thereof
• A61K 33/24 - Heavy metals; Compounds thereof
• A61P 31/12 - Antivirals

Abstract

Provided herein are methods of detecting single molecules that include binding single molecules in a sample solution to a first surface of an optically transparent substrate include the optically transparent substrate is free of a metallic coating. In some embodiments, the methods include irradiating the first surface of the substrate with an incident light having an incident angle selected to achieve total internal reflection of the incident light, thereby scattering light from the first surface and from the single molecules bound to the surface in which a wavelength of the incident light is between 10 nm and 350 pm and the optically transparent substrate has a refractive index at the wavelength of the incident light exceeding that of the sample solution, and collecting an image that captures interference between evanescent light scattered from the single molecules and the first surface. Systems and additional methods are also provided.

IPC Classes  ?

• G01N 21/33 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
• G01N 21/64 - Fluorescence; Phosphorescence
• G01N 21/47 - Scattering, i.e. diffuse reflection

Abstract

Provided herein are methods for multiplexed LAMP-based detection of multiple target nucleic acids in parallel at a single reaction temperature. In particular, provided herein are methods for performing a plurality of LAMP reactions in parallel using the addition of LAMP reaction temperature-shifting agents to better optimize a subset of the LAMP reactions to a single reaction temperature. For certain LAMP reactions, provided herein are LAMP primer sets and respective LAMP temperature-shifting parameters to provide efficient LAMP readouts at specific temperatures. Also provided herein are methods for increasing end-point signal-to-noise ratios of LAMP assays based on the detection of a fluorescent intercalating-dye in an amplification product.

IPC Classes  ?

• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/66 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase

Abstract

A method for fabricating a layered sorbent film is disclosed. The method includes forming a first sorbent layer by adhering a particulate sorbent material to a first adhesive surface of an adhesive film, the adhesive film further including a second adhesive surface coupled to a sacrificial liner. The method also includes removing the sacrificial liner from the adhesive film by exposure to a release medium, uncovering the second adhesive surface, and then forming a second sorbent layer by adhering the particulate sorbent material to the uncovered second adhesive surface. The method may also include separating a first release liner from the first adhesive surface of the adhesive film, uncovering the first adhesive surface. The sacrificial liner may be sufficiently rigid that while the sacrificial liner is coupled to the second adhesive surface, the first release liner may be removed from the adhesive film without causing mechanical damage.

IPC Classes  ?

• B01J 20/32 - Impregnating or coating
• B01D 53/62 - Carbon oxides
• B01J 20/26 - Synthetic macromolecular compounds
• B01J 20/30 - Processes for preparing, regenerating or reactivating
• B01J 20/22 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material

Abstract

The invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1 has any of the values described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful as cytoprotective agents.

IPC Classes  ?

• C07D 279/18 - [b, e]-condensed with two six-membered rings
• C07D 279/20 - [b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
• C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

A pneumatic-driven fluidic cartridge and systems and methods for operating the same. The cartridge includes a substrate layer, an actuator layer, and an elastic layer. A fluid channel formed in a surface of the substrate layer includes a first chamber and a second chamber separated by a block section. The actuator layer includes a lever positioned to extend across the block section. The elastic layer is positioned between the substrate layer and the actuator layer. The lever applies a force to the elastic layer restricts fluid flow from the first chamber to the second chamber and is configured to bend outwardly opening a channel between the block section and the elastic layer exceeds the first threshold pressure.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urine; Haemocytometers

Abstract

Provided herein are systems for the label-free detection of target molecules in samples. The systems include a sensor probe positioned in a sensing region and configured to bind to receptors for the target molecules. The systems also include electrodes configured to expose the sensor probe to an alternating electric field, and a light source optically coupled to the sensor probe and configured to provide light along a length of the sensor probe. In addition, the systems also include a position sensitive photodetector configured to detect a position of light exiting the sensor probe, and a processor configured to assess, based at least in part on the position of the light exiting the sensor probe, an amplitude of oscillation of the sensor at a frequency of the alternating electric field and a direction of a displacement of the sensor. Additional systems and related methods are also provided.

IPC Classes  ?

• G01N 21/62 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
• G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor
• G01N 21/63 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited

Abstract

Methods, systems, and apparatus, including wetness monitoring systems comprising a smart diaper comprising: asensorial battery comprising at least two electrodes; and a transmitter, wherein the sensorial battery is configured to provide electric current to the transmitter in the presence of water or urine, and wherein the transmitter is configured to emit a signal comprising a unique identifier when the electric current is received from the sensorial battery; and a computing device comprising: a receiver; a user interface; one or more processors; and a computer-readable storage device coupled to the one or more processors and having instructions stored thereon which, when executed by the one or more processors, cause the one or more processors to perform operations comprising: receiving, via the receiver, the signal emitted by the transmitter, and providing, via the user interface, an indication that the smart diaper is wet.

IPC Classes  ?

• A61F 13/15 - Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators

Abstract

Transparent models are generated for computer vision and image recognition utilizing deep learning non-transparent black box models. An explainable Al is generated by training a Convolutional Neural Network to classify objects and training a multi-layer perceptron to recognize both the objects and parts of the objects. An image having an object embedded therein is received. The CNN and explainable Al model are executed within an image recognition system to generate a prediction of the object in the image via the explainable Al model, recognize parts of the object, provide the parts recognized within the object as evidence for the prediction of the object, and generate a description of why the image recognition system predicted the object in the image based on the evidence comprising the recognized parts.

IPC Classes  ?

• G06N 5/022 - Knowledge engineering; Knowledge acquisition

Abstract

in situin situ, high throughput, single-cell whole-genome sequencing technology developed for sequencing genomes in large heterogeneous cell populations. More specifically, the invention disclosed herein does not require cell sorting or isolation because it uses the cell membrane to separate each genome.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
• C40B 40/06 - Libraries containing nucleotides or polynucleotides, or derivatives thereof
• C40B 70/00 - Tags or labels specially adapted for combinatorial chemistry or libraries, e.g. fluorescent tags or barcodes
• G16B 25/20 - Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
• C40B 50/06 - Biochemical methods, e.g. using enzymes or whole viable microorganisms

Abstract

System and method for contactless vascular flow measurement are provided. Herein, a measurement circuit emits a radio frequency (RF) waveform toward a human peripheral body part and measures micro-vessel motion in an area of interest of the human peripheral body part based on reflections of the RF waveform. Accordingly, the measurement circuit can extrapolate vascular flow information in the human peripheral body part based on the measured micro- vessel motion. In a non-limiting example, the measurement circuit can detect inner organ vibrations to measure pulse rate, strength, and/or pressure caused by radial arterial blood flow changes at the human peripheral body part. By detecting and measuring the vascular flow via the RF waveform, the vascular flow measurement system provides a non-invasive approach to detect and/or prevent peripheral artery diseases. Further, the measurement circuit emits a very low power, non-ionizing RF waveform to help minimize potential health risks to a human body.

IPC Classes  ?

• A61B 5/0265 - Measuring blood flow using electromagnetic means, e.g. electromagnetic flow meter
• A61B 5/02 - Measuring pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography; Heart catheters for measuring blood pressure
• A61B 5/021 - Measuring pressure in heart or blood vessels
• A61B 5/0245 - Measuring pulse rate or heart rate using sensing means generating electric signals